Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Syros Pharmaceuticals Inc    SYRS

SYROS PHARMACEUTICALS INC

(SYRS)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 06:11pm EDT

Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Definitive Material Agreement.

On January8, 2019, Syros Pharmaceuticals,Inc., as tenant (the “Company”), and DIV 35 CPD, LLC, as landlord (the “Landlord”), entered into a Lease Agreement (the “Lease”) with respect to approximately 52,859 square feet of space in a building commonly known and numbered as 35 CambridgePark Drive in Cambridge, Massachusetts (the “Premises”).

The term of the Lease commences upon the Landlord’s delivery of the Premises to Company broom clean and free of all occupants, which is expected to occur on or about February1, 2019 (the “Commencement Date”) and shall continue until February28, 2030, unless earlier terminated in accordance with the terms of the Lease (the “Lease Term”). The Company has (i)the option to extend the Lease Term for one (1)additional ten (10)year period, and (ii)a right of first offer on space on the fifth floor and first floor of the building, consisting of 63,121 rentable square feet or less in the aggregate, subject to the terms and conditions of the Lease.

The initial fixed rental rate is $67.50 per rentable square foot of the Premises per annum, and will increase at a rate of three percent (3%) per year, with base rent first becoming due on March1, 2020. Under the terms of the Lease, the Landlord will provide an allowance in an amount not to exceed $9,514,620 (calculated at a rate of $180 per rentable square foot of the Premises) toward the cost of completing the initial buildout of the Premises. The Company will be required pay its share of operating expenses, taxes and any other expenses payable under the Lease.

The Lease is filed as Exhibit10.1 to this Current Report on Form8-K,and the above description of the Lease is qualified in its entirety by reference to such exhibit.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth above in Item 1.01 of this Current Report on Form8-Kregarding the Leaseis incorporated into this Item 2.03 by reference.

Item 9.01. Financial Statements and Exhibits.

Syros Pharmaceuticals, Inc. Exhibit
EX-10.1 2 a19-2322_1ex10d1.htm EX-10.1 Exhibit 10.1   Execution Copy   LEASE   between   DIV 35 CPD,…
To view the full exhibit click here

About Syros Pharmaceuticals,Inc. (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

The post Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYROS PHARMACEUTICALS INC
03/07SYROS PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2018 Financial Resu..
BU
03/07SYROS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
03/06SYROS PHARMACEUTICALS : to Participate in Upcoming Investor Conferences in March
BU
02/28SYROS PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2018 Financial Re..
BU
02/27SYROS PHARMACEUTICALS : to Present New Preclinical Data on Its Selective CDK7 In..
BU
01/11SYROS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creati..
AQ
01/07SYROS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial ..
AQ
01/06SYROS PHARMACEUTICALS : Announces Strategic Priorities and Expected Milestones
BU
01/04SYROS PHARMACEUTICALS : to Present at 37th Annual J.P. Morgan Healthcare Confere..
AQ
01/03SYROS PHARMACEUTICALS : to Present at 37th Annual J.P. Morgan Healthcare Confere..
BU
More news
Financials ($)
Sales 2019 1,72 M
EBIT 2019 -78,4 M
Net income 2019 -78,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 176x
Capi. / Sales 2020 5,25x
Capitalization 302 M
Chart SYROS PHARMACEUTICALS INC
Duration : Period :
Syros Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYROS PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 16,0 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Nancy A. Simonian President, Chief Executive Officer & Director
Peter Wirth Chairman
Joseph J. Ferra Chief Financial Officer
Eric R. Olson Chief Scientific Officer
David A. Roth Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SYROS PHARMACEUTICALS INC65.53%302
CSL LIMITED6.50%63 534
BIOGEN-27.98%42 629
ALEXION PHARMACEUTICALS33.74%29 098
SAMSUNG BIOLOGICS CO LTD--.--%19 732
GRIFOLS2.53%16 228